Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HEXA | P06865 | 1/20 | 0.32 |
| ▸ | HEXB | P07686 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482101 | 0.73 | PNP (0.31) | — | |
| SCHEMBL5489090 | 0.71 | NSD2 (0.36) | HEXAHEXBNPSR1 | |
| SCHEMBL5477817 | 0.68 | HEXA (0.35) | HEXAHEXB | |
| SCHEMBL17622541 | 0.64 | MAPK1 (0.48) | TSHRUSP2SMN1; SMN2GAAMAPT | |
| SCHEMBL11860447 | 0.64 | HEXA (0.38) | HSP90AA1HEXAHEXB | |
| SCHEMBL29290176 | 0.64 | MAPT (0.31) | MAPT | |
| SCHEMBL2072604 | 0.63 | HEXA (0.46) | POLBHSP90AA1HEXAHEXB | |
| SCHEMBL7822136 | 0.63 | BLM (0.47) | PDE5AUSP2POLBGAAMAPT | |
| SCHEMBL27762061 | 0.62 | GPR84 (0.44) | — | |
| SCHEMBL10725121 | 0.62 | CASP1 (0.46) | TSHRBACE1SMN1; SMN2ADORA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419158-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca AB (SE) | 2004-05-19 | — | — | EP | claimed |
| WO-2003024966-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-27 | — | — | WO | claimed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | PDE5A 187/4885TSHR 1627/4885USP2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.